Table 2. Multivariate Logistic Regression to Compare Individuals Who Did and Did Not Decrease Alcohol Use After Initiation of an AOM .

Characteristic	aOR (95% CI) (n = 7491)	P value
Age, y
18-29	1 [Reference]	NA
30-44	1.08 (0.90-1.30)	.42
45-54	1.02 (0.84-1.25)	.82
≥55	0.96 (0.77-1.19)	.70
Sex
Female	1 [Reference]	NA
Male	0.74 (0.64-0.85)	<.001
Race and ethnicity
Asian	1.19 (0.79-1.76)	.40
Black or African American	1.14 (0.90-1.43)	.29
White	1 [Reference]	NA
Othera	1.22 (0.89-1.68)	.21
Missing	1.10 (0.92-1.33)	.30
Obesity status at baselineb
Overweight	1 [Reference]	NA
Obesity class I	1.26 (1.07-1.48)	.005
Obesity class II	1.49 (1.26-1.77)	<.001
Obesity class III	1.63 (1.36-1.96)	<.001
Duration of follow-up, mean (SD), d	1.00 (1.00-1.00)	<.001
Weekly alcohol use at baselinec
Category 1	1 [Reference]	NA
Category 2	5.97 (5.17-6.91)	<.001
Category 3	19.18 (13.25-28.86)	<.001
AOM treatment
Metformin	1 [Reference]	NA
Bupropion/naltrexone	1.42 (1.01-1.99)	.04d
First-generation GLP-1 RA	1.22 (0.88-1.70)	.23
Second-generation GLP-1 RA	1.19 (0.91-1.55)	.20

Abbreviations: AOM, antiobesity medication; aOR, adjusted odds ratio; GLP-1 RA, glucagon-like peptide-1 receptor agonist; NA, not applicable.

^a Includes American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, or multiracial.

^b Overweight was defined as body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of 25 to less than 30; class I obesity, BMI of 30 to less than 35; class II obesity, BMI of 35 to less than 40; class III obesity: BMI of 40 or greater.

^c Category 0, indicates none; category 1, 1 to 3 drinks for females and 1 to 6 drinks for males; category 2, 4 to 6 drinks for females and 7 to 14 drinks for males; category 3, at least 7 drinks for females and at least 15 for males.

^d This was no longer significant when accounting for weight loss.